Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDO2 | P48775 | 7/20 | 1.00 |
| ▸ | IDO2 | Q6ZQW0 | 7/20 | 1.00 |
| ▸ | IDO1 | P14902 | 6/20 | 1.00 |
| ▸ | LMNA | P02545 | 5/20 | 0.63 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.63 |
| ▸ | NPC1 | O15118 | 2/20 | 0.63 |
| ▸ | RAB9A | P51151 | 2/20 | 0.63 |
| ▸ | HTT | P42858 | 2/20 | 0.63 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.63 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.63 |
| ▸ | MAPT | P10636 | 1/20 | 0.63 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.63 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.63 |
| ▸ | NTRK2 | Q16620 | 1/20 | 0.63 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.63 |
| ▸ | APAF1 | O14727 | 2/20 | 0.59 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.57 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.57 |
| ▸ | POLB | P06746 | 2/20 | 0.57 |
| ▸ | TOP2A | P11388 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31510894 | 0.84 | TDO2 (0.73) | TDO2IDO2IDO1LMNAKMT2A | |
| SCHEMBL17830821 | 0.84 | TDO2 (0.73) | TDO2IDO2IDO1LMNAKMT2A | |
| SCHEMBL9885126 | 0.81 | IDO1 (0.68) | TDO2IDO2IDO1LMNAKMT2A | |
| Tryptanthrin SCHEMBL29359262 | 0.78 | TDO2 (1.00) | TDO2IDO2IDO1LMNAKMT2A | |
| Tryptanthrin SCHEMBL2426211 | 0.78 | TDO2 (1.00) | TDO2IDO2IDO1LMNAKMT2A | |
| SCHEMBL17830822 | 0.77 | TDO2 (0.62) | TDO2IDO2IDO1LMNAKMT2A | |
| SCHEMBL9103137 | 0.77 | TDO2 (0.62) | TDO2IDO2IDO1LMNAKMT2A | |
| SCHEMBL26614085 | 0.77 | TDO2 (0.62) | TDO2IDO2IDO1LMNAKMT2A | |
| SCHEMBL31382854 | 0.77 | TDO2 (0.62) | TDO2IDO2IDO1LMNAKMT2A | |
| Mecloqualone SCHEMBL113419 | 0.75 | ALDH1A1 (0.73) | TDO2IDO2IDO1LMNAMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9630969-B2 | N-alkyl tryptanthrin derivative, preparation method for same, and application thereof | SHANGHAI TIN TSZ BIO VALLEY BIOLOGICAL ENGINEERING CO., LTD (CN) | 2017-04-25 | — | — | US | disclosed |
| US-9630969-B2 | N-alkyl tryptanthrin derivative, preparation method for same, and application thereof | SHANGHAI TIN TSZ BIO VALLEY BIOLOGICAL ENGINEERING CO., LTD (CN) | 2017-04-25 | — | — | US | disclosed |
| US-20160168152-A1 | N-ALKYL TRYPTANTHRIN DERIVATIVE, PREPARATION METHOD FOR SAME, AND APPLICATION THEREOF | SHANGHAI TIN TSZ BIO VALLEY BIOLOGICAL ENGINEERING CO., LTD (CN) | 2016-06-16 | — | — | US | disclosed |
| US-20160168152-A1 | N-ALKYL TRYPTANTHRIN DERIVATIVE, PREPARATION METHOD FOR SAME, AND APPLICATION THEREOF | SHANGHAI TIN TSZ BIO VALLEY BIOLOGICAL ENGINEERING CO., LTD (CN) | 2016-06-16 | — | — | US | disclosed |
| US-20120244182-A1 | USE OF TRYPTANTHRIN COMPOUNDS FOR IMMUNE POTENTIATION | NOVARTIS VACCINES AND DIAGNOSTICS, INC. (US) | 2012-09-27 | — | — | US | disclosed |
| US-20120244182-A1 | USE OF TRYPTANTHRIN COMPOUNDS FOR IMMUNE POTENTIATION | NOVARTIS VACCINES AND DIAGNOSTICS, INC. (US) | 2012-09-27 | — | — | US | disclosed |
| US-20120244182-A1 | USE OF TRYPTANTHRIN COMPOUNDS FOR IMMUNE POTENTIATION | NOVARTIS VACCINES AND DIAGNOSTICS, INC. (US) | 2012-09-27 | — | — | US | disclosed |
| EP-1594524-B1 | USE OF TRYPTANTHRIN COMPOUNDS FOR IMMUNE POTENTIATION | NOVARTIS VACCINES & DIAGNOSTIC (US) | 2012-08-15 | — | — | EP | disclosed |
| EP-1594524-B1 | USE OF TRYPTANTHRIN COMPOUNDS FOR IMMUNE POTENTIATION | NOVARTIS VACCINES & DIAGNOSTIC (US) | 2012-08-15 | — | — | EP | disclosed |
| US-8193185-B2 | Administering a tryptanthrin compound, e.g., 8-nitroindolo[2,1-b]quinazoline-6,12-dione, to potentiate the immune response to an antigen; immunostimulants; small molecule immune potentiators; immunotherapy for infectious diseases; anticarcinogenic agents; vaccine adjuvant compositions and kits | NOVARTIS VACCINES AND DIAGNOSTICS, INC. (US) | 2012-06-05 | — | — | US | disclosed |
| US-8193185-B2 | Administering a tryptanthrin compound, e.g., 8-nitroindolo[2,1-b]quinazoline-6,12-dione, to potentiate the immune response to an antigen; immunostimulants; small molecule immune potentiators; immunotherapy for infectious diseases; anticarcinogenic agents; vaccine adjuvant compositions and kits | NOVARTIS VACCINES AND DIAGNOSTICS, INC. (US) | 2012-06-05 | — | — | US | disclosed |
| US-8193185-B2 | Administering a tryptanthrin compound, e.g., 8-nitroindolo[2,1-b]quinazoline-6,12-dione, to potentiate the immune response to an antigen; immunostimulants; small molecule immune potentiators; immunotherapy for infectious diseases; anticarcinogenic agents; vaccine adjuvant compositions and kits | NOVARTIS VACCINES AND DIAGNOSTICS, INC. (US) | 2012-06-05 | — | — | US | disclosed |
| US-8012987-B2 | Indolo[2,1-b] quinazole-6,12-dione antimalarial compounds and methods of treating malaria therewith | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY OF THE ARMY (US) | 2011-09-06 | — | — | US | disclosed |
| US-8012987-B2 | Indolo[2,1-b] quinazole-6,12-dione antimalarial compounds and methods of treating malaria therewith | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY OF THE ARMY (US) | 2011-09-06 | — | — | US | disclosed |
| US-5441955-A | Tuberculosis | PATHOGENESIS CORPORATION (US) | 1995-08-15 | — | — | US | disclosed |
| WO-1995013807-A1 | INDOLO[2,1-b]QUINAZOLINE-6,12-DIONE ANTIBACTERIAL COMPOUNDS AND METHODS OF USE THEREOF | PATHOGENESIS CORPORATION (US) | 1995-05-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120244182-A1 | USE OF TRYPTANTHRIN COMPOUNDS FOR IMMUNE POTENTIATION | TPSG1, TPSB2, TPSAB1 | TDO2 66/4885IDO2 19/4885IDO1 20/4885 |
| US-20160168152-A1 | N-ALKYL TRYPTANTHRIN DERIVATIVE, PREPARATION METHOD FOR SAME, AND APPLICATION THEREOF | IDO1, IDO2, TPH1 | TDO2 9/4885IDO2 2/4885IDO1 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.